Starpharma (ASX:SPL) has signed an expanded DEP research agreement with Genentech, a member of the Roche Group, to evaluate additional DEP drug conjugates.
The company said this new DEP program is in addition to the current research program that was signed in December 2021.
Starpharma will design and synthesize DEP dendrimer conjugates and provide them to Genentech for testing and characterisation. The agreement terms for this new program are the same as for the agreement signed in December 2021.
Starpharma has a number of other DEP partnerships with international pharmaceutical and biotechnology companies, including AstraZeneca, MSD and Chase Sun.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
